460,000 EUR Grant to Advance Cutting-Edge T Cell Therapy for Sarcoma Patients

The National Strategy for gene and cell-based therapies funds the University Hospital Regensburg and the Leibniz Institute for immunotherapy to advance cutting-edge T cell therapy for sarcoma patients.